< Back to previous page

Project

GPCR dimerization in AD: From brain expression to therapeutic potential.

GPCR targets are considered highly "druggable" and a growing interest in GPCRs forming hetero- or homodimers as possible newpharmacological targets in a variety of diseases, including AD and related dementias, has been expressed. The translation ofGPCR heterodimers and mosaics to pharmaceutical drug discovery and development is however in its infancy and hampered bythe lack of appropriate tools to study these bioconjugates, as well as insufficient understanding of which interactions are importantand (patho)physiologically relevant. This project will provide a systematic screening of GPCR expression and subcellularlocalisation in human brain tissue, as well as in a valid amyloidosis mouse model. Latter model will be applied to provide the veryfirst proof-of-concept that targeting an AD-relevant GPCR heterodimer with a bivalent ligand may provide a novel therapeuticapproach that could cause a major shift in AD treatment.
Date:1 May 2018 →  30 Apr 2019
Keywords:ALZHEIMER'S DISEASE
Disciplines:Genetics, Systems biology, Molecular and cell biology